Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder

British Journal of Cancer

Volumn 111, Issue 3, 2014, Pages 444-451

  Hermanns, T ^a,b   Bhindi, B ^b,c   Wei, Y ^a   Yu, J ^a   Noon, A P ^a,b   Richard, P O ^a,b   Bhatt, J R ^a,b   Almatar, A ^a,b   Jewett, M A S ^a,b   Fleshner, N E ^a,b   Zlotta, A R ^b,d   Templeton, A J ^a   Kulkarni, G S ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD CELL COUNT; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CYSTECTOMY; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; HYDRONEPHROSIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL TO LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTE COUNT; TRANSITIONAL CELL CARCINOMA; URETHROSCOPY;

AGED; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84905280511     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.305     Document Type: Article

References (27)

1. Austin PC, Mamdani MM, van Walraven C, Tu JV (2006) Quantifying the impact of survivor treatment bias in observational studies. J Eval Clin Prac 12(6): 601-612.
2. Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA (2011) Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 107(1): 58-62.
3. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS. Urologic Diseases in America P (2013) Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 119(17): 3219-3227.
4. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. National Comprehensive Cancer N (2013) Bladder cancer. J Natl Compr Canc Netw 11(4): 446-475.
5. Demirtas A, Sabur V, Akinsal EC, Demirci D, Ekmekcioglu O, Gulmez I, Tatlisen A (2013) Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in patients undergoing radical cystectomy? TheScientificWorldJournal 2013: 703579.
6. Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W (2005) Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95(6): 786-790.
7. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1): 45-57.
8. Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79(5): 1085-1091.
9. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6): 883-899.
10. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Cri Rev Oncol Hematol 88(1): 218-230.
11. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
12. Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC curves. Biometrics 61(1): 92-105.
13. Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14(15): 1707-1723.
14. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK (2013) Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol 27(8): 1046-1050.
15. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J (2013) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol; e-pub ahead of print 28 August 2013; doi:10.1016/j.eururo.2013.08.033.
16. Lin D, Wei LJ (1989) The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84(408): 1074-1078.
17. Lipscombe LL, Chan WW, Yun L, Austin PC, Anderson GM, Rochon PA (2013) Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56(3): 476-483.
18. Lu L, Liu C (2006) Using the Time Dependent ROC Curve to Build Better Survival Model in SAS. NorthEast SAS Users Group Conferences (NESUG); Philadelphia, 17-20 September 2006.
19. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G (2012) A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 62(3): 523-533.
20. Perkins NJ, Schisterman EF (2006) The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 163(7): 670-675.
21. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4): 695-699.
22. Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, Frenkel E (2011) Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 117(2): 276-282.
23. Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25(1): 127-141.
24. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51(1): 137-149.
25. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 63(1): 58-66.
26. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6): dju124.
27. Thomas F, Rosario DJ, Rubin N, Goepel JR, Abbod MF, Catto JW (2012) The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm? Cancer 118(22): 5525-5534.